Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2012

01-09-2012

The optimize project: beyond first-line therapy in metastatic renal cell carcinoma

Authors: Daniel Castellano, Joaquim Bellmunt

Published in: Cancer and Metastasis Reviews | Special Issue 1/2012

Login to get access

Excerpt

The treatment of patients with metastatic renal cell carcinoma (mRCC) has changed dramatically over the past 5 years, and a new paradigm has evolved. Angiogenesis in general, and the vascular endothelial growth factor and mammalian target of rapamycin pathways in particular, are validated targets in renal cell carcinoma. …
Metadata
Title
The optimize project: beyond first-line therapy in metastatic renal cell carcinoma
Authors
Daniel Castellano
Joaquim Bellmunt
Publication date
01-09-2012
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue Special Issue 1/2012
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-012-9393-5

Other articles of this Special Issue 1/2012

Cancer and Metastasis Reviews 1/2012 Go to the issue

ReviewPaper

Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma

ReviewPaper

Quality of life and supportive care for patients with metastatic renal cell carcinoma

ReviewPaper

Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action

ReviewPaper

The role of pharmacogenomics in metastatic renal cell carcinoma

ReviewPaper

Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits